Articles

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers

Immune checkpoint therapy (ICT) can produce durable antitumor responses in various cancer types; however, the responses are not universal, and the predictive biomarkers are urgently needed. Growing evidence po...

Authors: Peng Zhang and Yixuan Huang

COVID-19 vaccines for patients with cancer: benefits likely outweigh risks

Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has gen...

Authors: Joyce K. Hwang, Tian Zhang, Andrew Z. Wang and Zihai Li

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study ...

Authors: Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang…

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. H...

Authors: Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach and Erin Hertlein

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in pati...

Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry…

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

An amendment to this paper has been published and can be accessed via the original article.

Authors: Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo…

Correction to: Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer

An amendment to this paper has been published and can be accessed via the original article.

Authors: Senlin Zhao, Yushuai Mi, Bingjie Guan, Binbin Zheng, Ping Wei, Yanzi Gu, Zhengxiang Zhang, Sanjun Cai, Ye Xu, Xinxiang Li, Xuefeng He, Xinyang Zhong, Guichao Li, Zhiyu Chen and Dawei Li

m⁶A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis

Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su

Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

An amendment to this paper has been published and can be accessed via the original article.

Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers

The emerging role of KDM5A in human cancer

Histone methylation is a key posttranslational modification of chromatin, and its dysregulation affects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulat...

Authors: Guan-Jun Yang, Ming-Hui Zhu, Xin-Jiang Lu, Yan-Jun Liu, Jian-Fei Lu, Chung-Hang Leung, Dik-Lung Ma and Jiong Chen

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

An amendment to this paper has been published and can be accessed via the original article.

Authors: Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie José Kersten, Marcel Spaargaren and Steven T. Pals

Correction to: Novel and emerging therapies for B cell lymphoma

An amendment to this paper has been published and can be accessed via the original article.

Authors: Sabarish Ayyappan and Kimi Maddocks

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subse...

Authors: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou and Kongming Wu

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will...

Authors: Yun Liang, Hui Liu, Zheming Lu, Wen Lei, Chaoting Zhang, Ping Li, Aibin Liang, Ken H. Young and Wenbin Qian

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data fro...

Authors: Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok-Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-peng Yeh, Yuqin Song, Yok Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, HyeJin Kim, Min Qing…

Challenges and advances in clinical applications of mesenchymal stromal cells

Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials a...

Authors: Tian Zhou, Zenan Yuan, Jianyu Weng, Duanqing Pei, Xin Du, Chang He and Peilong Lai

FGFR-TKI resistance in cancer: current status and perspectives

Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved g...

Authors: Sitong Yue, Yukun Li, Xiaojuan Chen, Juan Wang, Meixiang Li, Yongheng Chen and Daichao Wu

Clonal evolution in liver cancer at single-cell and single-variant resolution

Genetic heterogeneity of tumor is closely related to its clonal evolution, phenotypic diversity and treatment resistance, and such heterogeneity has only been characterized at single-cell sub-chromosomal scale...

Authors: Xianbin Su, Linan Zhao, Yi Shi, Rui Zhang, Qi Long, Shihao Bai, Qing Luo, Yingxin Lin, Xin Zou, Shila Ghazanfar, Kun Tao, Guoliang Yang, Lan Wang, Kun-Yan He, Xiaofang Cui, Jian He…

Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes

B7-H3, an immune-checkpoint molecule and a transmembrane protein, is overexpressed in non-small cell lung cancer (NSCLC), making it an attractive therapeutic target. Here, we aimed to systematically evaluate t...

Authors: Jie Liu, Shuo Yang, Bihui Cao, Guangyu Zhou, Fengjuan Zhang, Yuan Wang, Rixin Wang, Lipeng Zhu, Ya Meng, Cong Hu, Hui Liang, Xu Lin, Kangshun Zhu, Guokai Chen, Kathy Qian Luo, Lijun Di…

Antibody–drug conjugates in solid tumors: a look into novel targets

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly descri...

Authors: Carmen Criscitiello, Stefania Morganti and Giuseppe Curigliano

Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells

TNBC is the most aggressive breast cancer with higher recurrence and mortality rate than other types of breast cancer. There is an urgent need for identification of therapeutic agents with unique mode of actio...

Authors: Yahui Ding, Xiaoping Chen, Can Liu, Weizhi Ge, Qin Wang, Xin Hao, Mengmeng Wang, Yue Chen and Quan Zhang

Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort

Accurate interpretation of BRCA1/2 variants is critical for risk assessment and precise treatment of breast cancer (BC). Hence, the establishment of an ethnicity-based BRCA1/2 variant database of the Chinese popu...

Authors: Yun Liu, Honglian Wang, Xin Wang, Jiaqi Liu, Junjian Li, Xiang Wang, Yun Zhang, Zhigang Bai, Qinghua Zhou, Ying Wu, Yi Shen, Xiaoling Weng, Fatao Liu, Jiancheng Guo, Lijun Di, Olivier Gires…

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia

Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutat...

Authors: Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne V. Abruzzo…

STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib

Dysregulation of both mitochondrial biogenesis and mitophagy is critical to sustain oncogenic signaling pathways. However, the mechanism of mitophagy in promoting hepatocellular carcinoma (HCC) progression rem...

Authors: Yahui Zheng, Chong Huang, Lu Lu, Kangkang Yu, Jing Zhao, Mingquan Chen, Lu Liu, Qingfeng Sun, Zhifei Lin, Jianming Zheng, Jinhong Chen and Jubo Zhang

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer

Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and...

Authors: Brooke Benner and William E. Carson

Targeting hypoxic tumor microenvironment in pancreatic cancer

Attributable to its late diagnosis, early metastasis, and poor prognosis, pancreatic cancer remains one of the most lethal diseases worldwide. Unlike other solid tumors, pancreatic cancer harbors ample stromal...

Authors: Jinxin Tao, Gang Yang, Wenchuan Zhou, Jiangdong Qiu, Guangyu Chen, Wenhao Luo, Fangyu Zhao, Lei You, Lianfang Zheng, Taiping Zhang and Yupei Zhao

The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials

Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibito...

Authors: Anwaar Saeed, Robin Park and Weijing Sun

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety o...

Authors: Yuankai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang…

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

The survival and proliferation of multiple myeloma (MM) cells in the bone marrow (BM) critically depend on interaction with stromal cells expressing the chemokine CXCL12. CXCL12 regulates the homing to the BM ...

Authors: Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie José Kersten, Marcel Spaargaren and Steven T. Pals

Regulation of PD-L1 expression in the tumor microenvironment

Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major ...

Authors: Ming Yi, Mengke Niu, Linping Xu, Suxia Luo and Kongming Wu

Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism

Key hepatic molecules linking gut dysbiosis and hepatocarcinogenesis remain largely unknown. Gut-derived gut microbiota contains pathogen-associated molecular patterns (PAMPs) that may circulate into the liver...

Authors: Yi Zhou, Liang Hu, Wenqing Tang, Dongping Li, Lijie Ma, Hongchun Liu, Shuncai Zhang, Xiaojie Zhang, Ling Dong, Xizhong Shen, She Chen, Ruyi Xue and Si Zhang

Targeting oncogenic Notch signaling with SERCA inhibitors

P-type ATPase inhibitors are among the most successful and widely prescribed therapeutics in modern pharmacology. Clinical transition has been safely achieved for H⁺/K⁺ ATPase inhibitors such as omeprazole and Na

Authors: Luca Pagliaro, Matteo Marchesini and Giovanni Roti

NK cell-based cancer immunotherapy: from basic biology to clinical development

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activat...

Authors: Sizhe Liu, Vasiliy Galat, Yekaterina Galat4, Yoo Kyung Annie Lee, Derek Wainwright and Jennifer Wu

HOMER3 facilitates growth factor-mediated β-Catenin tyrosine phosphorylation and activation to promote metastasis in triple negative breast cancer

HOMER family scaffolding proteins (HOMER1-3) play critical roles in the development and progression of human disease by regulating the assembly of signal transduction complexes in response to extrinsic stimuli...

Authors: Qinghua Liu, Lixin He, Siqi Li, Fengyan Li, Guangzheng Deng, Xinjian Huang, Muwen Yang, Yunyun Xiao, Xiangfu Chen, Ying Ouyang, Jinxin Chen, Xuxia Wu, Xi Wang, Libing Song and Chuyong Lin

How we treat mature B-cell neoplasms (indolent B-cell lymphomas)

Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an ex...

Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell and Erel Joffe

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patien...

Authors: Li Xuan and Qifa Liu

Stable colony-stimulating factor 1 fusion protein treatment increases hematopoietic stem cell pool and enhances their mobilisation in mice

Prior chemotherapy and/or underlying morbidity commonly leads to poor mobilisation of hematopoietic stem cells (HSC) for transplantation in cancer patients. Increasing the number of available HSC prior to mobi...

Authors: Simranpreet Kaur, Anuj Sehgal, Andy C. Wu, Susan M. Millard, Lena Batoon, Cheyenne J. Sandrock, Michelle Ferrari-Cestari, Jean-Pierre Levesque, David A. Hume, Liza J. Raggatt and Allison R. Pettit

The management of metastatic GIST: current standard and investigational therapeutics

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or PDGFRα. Determination of the G...

Authors: Ciara M. Kelly, Laura Gutierrez Sainz and Ping Chi

MEK inhibitors for the treatment of non-small cell lung cancer

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the pro...

Authors: Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li and Qiming Wang

Novel targeted therapies of T cell lymphomas

T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. ...

Authors: Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak and Grzegorz K. Przybylski

New agents and regimens for diffuse large B cell lymphoma

As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and t...

Authors: Liang Wang, Lin-rong Li and Ken H. Young

Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients

Immunotherapy has been a new standard for recurrent/metastatic head and neck cancers (R/M HNC). One of the prominent characteristics of cancer immunotherapy is the induction of immune memory followed by endure...

Authors: Gaili Chen, Qiuji Wu, Huangang Jiang, Zheng Li, Xinying Hua, Xiaoyan Hu, Haijun Yu, Conghua Xie and Yahua Zhong

MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

Cell death escape is one of the most prominent features of tumor cells and closely linked to the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic family member myeloid ...

Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were n...

Authors: Jeong A. Park and Nai-Kong V. Cheung

Trajectory of chemical cocktail-induced neutrophil reprogramming

Hematopoietic reprogramming holds great promise for generating functional target cells and provides new angle for understanding hematopoiesis. We reported before for the first time that diverse differentiated ...

Authors: Yi Zhou, Chuijin Wei, Shumin Xiong, Liaoliao Dong, Zhu Chen, Sai-Juan Chen and Lin Cheng

Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets

Proteomic characterization of cancers is essential for a comprehensive understanding of key molecular aberrations. However, proteomic profiling of a large cohort of cancer tissues is often limited by the conve...

Authors: Yangying Zhou, T. Mamie Lih, Jianbo Pan, Naseruddin Höti, Mingming Dong, Liwei Cao, Yingwei Hu, Kyung-Cho Cho, Shao-Yung Chen, Rodrigo Vargas Eguez, Edward Gabrielson, Daniel W. Chan, Hui Zhang and Qing Kay Li

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although most of the mechanisms of acquired ...

Authors: Yulong Fu, Yang Zhang, Zhe Lei, Ting Liu, Tingting Cai, Anqi Wang, Wenwen Du, Yuanyuan Zeng, Jianjie Zhu, Zeyi Liu and Jian-an Huang

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Natural killer (NK) cells are a critical component of the innate immune system. Chimeric antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding antigens, creating major opportuni...

Authors: Ahmet Yilmaz, Hanwei Cui, Michael A. Caligiuri and Jianhua Yu

Natural killer cell-based immunotherapy for acute myeloid leukemia

Despite considerable progress has been achieved in the treatment of acute myeloid leukemia over the past decades, relapse remains a major problem. Novel therapeutic options aimed at attaining minimal residual ...

Authors: Jing Xu and Ting Niu

Targeting the Wnt/β-catenin signaling pathway in cancer

The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investi...

Authors: Ya Zhang and Xin Wang